Update on implant related infections in orthopaedic surgery. Diagnosis and treatment;Diagnostic et traitement des infections d'implants orthopédiques

Revue Medicale Suisse

Volumn 5, Issue 230, 2009, Pages 2563-2568

  Borens, Olivier ^a   Nussbaumer, François ^a   Baalbaki, Rayan ^a   Trampuz, Andrej ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DAPTOMYCIN; FUSIDIC ACID; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; NAFCILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ALGORITHM; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BIOFILM; CLINICAL PRACTICE; DEBRIDEMENT; DEVICE INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ENDOPROSTHESIS LOOSENING; ENTEROBACTERIACEAE; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIP PROSTHESIS; HISTOLOGY; HUMAN; IMPLANT; JOINT PROSTHESIS; KNEE PROSTHESIS; LABORATORY DIAGNOSIS; METAL IMPLANTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MIXED INFECTION; NONHUMAN; ORTHOPEDIC SURGERY; PAIN; PATHOGENESIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PROSTHESIS INFECTION; RECOMMENDED DRUG DOSE; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; TOTAL HIP PROSTHESIS;

HUMANS; ORTHOPEDIC PROCEDURES; PROSTHESIS-RELATED INFECTIONS;

EID: 76049128868     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther 2007;82:204-9.
2. ** Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351:1645-54.
3. Donlan RM. Biofilms: Microbial life on surfaces. Emerg Infect Dis 2002;8:881-90.
4. Steckelberg JM, Osmon DR. Prosthetic Joint Infection. In: Bisno AL and Waldvogel FA eds. 3rd. Washington: American Society for Microbiology, 2000;173-209.
5. Ochsner PE, Sirkin MS, Trampuz A. Acute infection. In: Ruedi RP and Murphy WM eds. Stuttgart: Thieme Verlag, 2006.
6. * Trampuz A, Hanssen AD, Osmon DR, et al. Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infection. Am J Med 2004;117:556-62.
7. ** Trampuz A, Piper KE, Jacobson MJ, et al. Sonication of removed hip and knee prostheses for improved diagnosis of infection. N Engl J Med 2007;357:654-63.
8. Trampuz A, Osmon DR, Hanssen AD, et al. Molecular and antibiofilm approaches to prosthetic joint infection. Clin Orthop 2003;414:69-88.
9. Brause BD. Infections with prostheses in bones and joints. In: Mandell GL, Bennett JE, and Dolin R eds. 6th. Washington: WB Saunders, 2005;1332-7.
10. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990;162:96-101
11. Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991;35:741-6.
12. Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994;33:959-67.
13. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537-41.
14. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992;14:1251-3.
15. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. J Bone Joint Surg Br 2005;87B:249-56.
16. Giulieri SG, Graber P, Ochsner PE, Zimmerli W. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection 2004;32:222-8.
17. Laffer RR, Graber P, Ochsner PE, Zimmerli W. Outcome of prosthetic knee-associated infection: Evaluation of 40 consecutive episodes at a single centre. Clin Microbiol Infect 2006;12:433-9.
18. Betsch BY, Eggti S, Siebenrock KA, et al. Treatment of joint prosthesis infection in accordance with current recommendations improves outcome. Clin Infect Dis 2008;46:1221-6.
19. Brandt CM, Sistrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997;24:914-9.
20. Tsukayama DT, Wicklund B, Gustilo RB. Suppressive antibiotic therapy in chronic prosthetic joint infections. Orthopedics 1991;14:841-4.
21. Crockarell JR, Hanssen AD, Osmon DR, Morrey BF. Treatment of infection with debridement and retention of the components following hip arthroplasty. J Bone Joint Surg Am 1998;80:1306-13.
22. Marculescu CE, Berbari EF, Hanssen AD, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis 2006;42:471-8.
23. Ure KJ, Amstutz HC, Nasser S, Schmalzried TP. Direct-exchange arthroplasty for the treatment of infection after total hip replacement. An average ten-year follow-up. J Bone Joint Surg Am 1998;80:961-8.
24. Raut VV, Siney PD, Wroblewski BM. One-stage revision of infected total hip replacements with discharging sinuses. J Bone Joint Surg Br 1994;76:721-4.
25. Sendi P, Rohrbach M, Graber P, et al. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis 2006;43:961-7.
26. Langlais F. Can we improve the results of revision arthroplasty for infected total hip replacement? J Bone Joint Surg Br 2003;85:637-40.
27. Trampuz A, Murphy CK, Rothstein DM, et al. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob Agents Chemother 2007;51:2540-5.